Brean Murray Carret & Co. Assumes Onyx Pharmaceuticals (ONXX) at Buy, Kyprolis is Key

Brean Murray Carret & Co. assumes coverage on Onyx Pharmaceuticals (NASDAQ: ONXX) with a Buy. PT $98.00.

"In the near term, we expect ONXX shares to be impacted mostly by early feedback from the clinical community on Kyprolis use and duration of treatment," the firm said. "Regorafenib should also contribute positive newsflow in the near term, with anticipated approval in October. Over the longer term, we believe ONXX shares will be impacted by Kyprolis label expansion and introduction of Oprozomib, the company’s oral proteasome inhibitor."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $82.52 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Resumes JD.com, Inc (JD) at Buy
• Cantor Fitzgerald Starts Materialise NV (MTLS) at Overweight, 'Well-Positioned to meet rising software demand'
• H.C. Wainwright Starts Processa Pharmaceuticals (PCSA) at Buy